# EB-MF-CAR-NK-01

Source: https://onco.cc/drugs/eb-mf-car-nk-01/  
OnCo record `eb-mf-car-nk-01` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EB-MF-CAR-NK-01 is an experimental bispecific antibody from Beijing Biotech in phase 2 trials for mesothelioma, aimed at Mesothelin and FAP.

## Summary

EB-MF-CAR-NK-01 is a bispecific antibody developed by Beijing Biotech. Its targets are Mesothelin and FAP. ClinicalTrials.gov describes the intervention as: Example investigational product: donor-derived allogeneic NK cells engineered to recognize both MSLN-positive tumour cells and FAPpositive stromal elements, manufactured under GMP. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in mesothelioma. The largest, NCT07510815, plans to enrol 36 participants with primary completion expected 2027-03-14. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: Mesothelin/FAP Dual-Target CAR-NK Cells
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: Bispecific antibody directed at Mesothelin and FAP, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of EB-MF-CAR-NK-01: https://clinicaltrials.gov/search?intr=EB-MF-CAR-NK-01

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/)
- targets: [FAP](https://onco.cc/targets/fap/), [Mesothelin](https://onco.cc/targets/mesothelin/)
- trials: [Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma](https://onco.cc/trials/nct07510815/), [Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer](https://onco.cc/trials/nct07066995/)

---
JSON: https://onco.cc/api/v1/entities/eb-mf-car-nk-01.json